Clinical Trial Update: Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing the effects of zoledronic acid and raloxifene on bone turnover markers in postmenopausal women with low bone mineral density.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Raloxifene (raloxifene)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis | Conditions: Osteoporosis | Phase 4 | Status: COMPLETED | Results posted: 2011-03-11